Fresenius stock sale cuts FMC stake and frees capital for growth

Fresenius completed the sale of 13.4 million Fresenius Medical Care shares on Thursday, November 12, at a placing price of 39.00 euros per share. The transaction generated gross proceeds of approximately 524 million euros and reduced Fresenius' financial investment in the separately listed dialysis company from approximately 25 percent to approximately 20 percent, according to the Deutsche Boerse release.

Fresenius stock traded at 53.45 euros on Lang & Schwarz at 12:13 CET on Friday, November 13, 0.30 percent above the Xetra close of Thursday, November 12. The comparison uses the previous Xetra session because the current Xetra session was still open.

Capital allocation after FMC sale

Fresenius said the net proceeds will be available for investment in its growth platforms and will support the capital allocation priorities of its FutureFresenius strategy. Chief Financial Officer Sara Hennicken described the transaction as another step in managing the Fresenius Medical Care investment and freeing capital for the company's REJUVENATE phase.

The sale extends a broader reduction in the holding. Since Fresenius Medical Care was deconsolidated, Fresenius has reduced its financial investment from approximately 32 percent to approximately 20 percent and has generated cumulative gross proceeds of approximately 2.3 billion euros, according to the announcement. Fresenius also sold 7.8 million Fresenius Medical Care shares in August.

The transaction was carried out through an accelerated bookbuild for institutional investors. Settlement is expected on Monday, November 16. Fresenius remains subject to a 90-day lock-up on its remaining Fresenius Medical Care shares, subject to customary exceptions.

Book gain enters fourth-quarter results

Fresenius expects the book gain from the sale to be in the low to mid double-digit million euro range. The gain will be reflected in the group's fourth-quarter 2026 results as a special item, separating the transaction effect from the underlying operating performance of Fresenius Kabi and Fresenius Helios.

For investors, the transaction improves financial flexibility but also reduces exposure to future movements in Fresenius Medical Care. The immediate financial benefit is therefore linked to capital deployment: the market will next assess whether Fresenius can translate the released funds into growth and whether the remaining stake continues to support the group's balance-sheet strategy.

German equities traded in the broader DAX market as investors weighed company-specific developments against the wider market backdrop.

More news and analyses on Fresenius stock